by Vineti | October 23, 2019
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former CEO and Chairman of cancer genomics trailblazer Foundation Medicine. He is a leading voice on how the life sciences will continue to…
by Heidi Hagen | October 17, 2019
Why is the distinction between the supply chain and value chain important in cell therapies, gene therapies, and personalized cancer vaccines? As it turns out, it all comes back to the patient.
by Tyler Wilson | October 10, 2019
Read about general approaches to UX and digital product design, and you see terms like "user delight" and "sparking delight" with increasing frequency. But sometimes, in the world of UX and product design, “delight” means getting out of the way.
by Amy DuRoss | September 19, 2019
This fall, it will be 15 years since regenerative medicine faced a crisis of funding and support in the United States -- and the public stood up to pave a path forward. Now, at this milestone, it’s time to look ahead, and think about how we continue…
by Heidi Hagen | August 27, 2019
Next month, my colleagues at Vineti and I will be speaking, writing, and presenting on a topic of critical importance to cell and gene therapy -- data management. Why now? Because in advanced therapeutics, data management is patient management. To…